Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - USD ($)		1 Months Ended	9 Months Ended
	Jul. 08, 2021	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		$ 0	$ 5,159,000
Novo Nordisk
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accounts receivable		0	0
Share Purchase Agreement, Upfront Payment	$ 60,000,000
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones			1,130,000,000
Revenue from License and Intellectual Property, Share Purchase Agreement			$ 0	$ 0
Milestone achievement, Clinical milestone		$ 40,000,000
Novo Nordisk | Transition services
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from License and Intellectual Property, Share Purchase Agreement	$ 700,000